Immunologic characterization of COVID-19 patients with hematological cancer

Maia, Catarina; Martín-Sánchez, Esperanza; Garcés, Juan-José; Cerio, Ascension Lopez Diaz de; Inogés, Susana; Landecho, Manuel F.; Gil-Alzugaray, Belén; Pérez, Cristina Fernández; Botta, Cirino; Zabaleta, Aintzane; Alegre, Félix; Rincón, César; Blanco, Laura; Sarvide, Sarai; Vilas-Zornoza, Amaia; Alignani, Diego; Moreno, Cristina; Paiva, Artur; Martinho, António; Alves, Rui; Colado, Enrique; Quirós, Covadonga; Olid, M.; Blanco, Andrés; Argemí, Josepmaria; Yuste, José Ramón

doi:10.3324/haematol.2020.269878

Cited by 14 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 92%

“…Limited data are available regarding the immunological landscape of COVID-19 in HM patients. A recent study [ 14 ] showed significantly decreased percentages of classical monocytes, immunoregulatory NK cells, double-positive T cells, and B cells, when compared to COVID-19 patients without HM. Another study [ 15 ] reported a protective effect of high CD8 + cell counts on COVID-19 related mortality, irrespective of the concomitant presence of B-cell deficiency.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

et al. 2021

View full text Add to dashboard Cite

The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.

show abstract

Section: Introductionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Data analysis was performed as described elsewhere [ 49 , 50 ]. Briefly, it was based on a multi-step bioinformatics approach: (1) reading FCS data; (2) building a self-organizing map (SOM) for clustering; (3) performing a dimensionality reduction through principal component analysis (PCA) and uniform manifold approximation and projection (UMAP); (4) perform a supervised identification of each cluster; (5) performing a statistical analysis on the abundance of each population according to their origin (ANOVA).…”

Section: Methodsmentioning

confidence: 99%

Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

et al. 2021

Self Cite

View full text Add to dashboard Cite

Motoneuronal loss is the main feature of amyotrophic lateral sclerosis, although pathogenesis is extremely complex involving both neural and muscle cells. In order to translationally engage the sonic hedgehog pathway, which is a promising target for neural regeneration, recent studies have reported on the neuroprotective effects of clobetasol, an FDA-approved glucocorticoid, able to activate this pathway via smoothened. Herein we sought to examine functional, cellular, and metabolic effects of clobetasol in a neurotoxic mouse model of spinal motoneuronal loss. We found that clobetasol reduces muscle denervation and motor impairments in part by restoring sonic hedgehog signaling and supporting spinal plasticity. These effects were coupled with reduced pro-inflammatory microglia and reactive astrogliosis, reduced muscle atrophy, and support of mitochondrial integrity and metabolism. Our results suggest that clobetasol stimulates a series of compensatory processes and therefore represents a translational approach for intractable denervating and neurodegenerative disorders.

show abstract

“…Clinical course and disease severity in COVID-19 is strongly associated with weaker immune response, bulk release of proinflammatory cytokines and the recruitment of neutrophils, monocytes and macrophages, which can generate an aggressive response, in some cases inappropriate, detrimental and harmful for the host [ 6 ], especially in cancer patients [ 7 , 8 ]. Recent reports disclosed the contribution of monocytes to the hyper-inflammatory phenotype, thus worsening disease severity [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Patients carrying hematological neoplasms have increased infection susceptibility, due to immunodeficiency, T-cell anergy, increased myeloid-derived suppressor cells and impairment of antigen presentation machinery [ 6 , 13 , 16 ], as a consequence of the malignancy itself. In multiple myeloma (MM), either anergic, dysfunctional effector lymphocytes or both, tumor-educated myeloid-derived suppressor cells and soluble mediators promote coordinately cancer immune-evasion [ 17 , 18 , 19 , 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

Romano

Cerchione

Conticello

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Clinical course of COVID-19 depends on several patient-specific risk factors, including immune function, that is largely compromised in cancer patients. Methods: We prospectively evaluated 120 adult consecutive patients (including 34 cases of COVID-19 breakthrough after two full doses of BNT162b2 vaccine) with underlying hematological malignancies and a SARS-CoV-2 infection, in terms of patient’s clinical outcome. Results: Among fully vaccinated patients the achievement of viral clearance by day 14 was more frequent than in unvaccinated patients. Increased 30-day mortality was associated with presence of active/progressing disease and absolute monocyte count lower than 400 cells/uL. Results of multivariable analysis in unvaccinated patients showed that the pre-infection absolute count of monocytes less or equal to 400 cells/mmc, active or progressive disease of the underlying hematological malignancy, the COVID-19 severity identified by hospitalization requirement and lack of viral clearance at 14 days were independent predictors of 1-year overall survival. Conclusions: Taken together, our results indicate that absolute monocyte count determined one month before any documented SARS-CoV-2 infection could identify patients affected by hematological neoplasms with increased risk of inferior overall survival.

show abstract

Immunologic characterization of COVID-19 patients with hematological cancer

Abstract: Not available.

Cited by 14 publications

References 13 publications

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

Contact Info

Product

Resources

About